Pertuzumab
Invasive Ductal Breast Carcinoma
Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
GBG Forschungs GmbH
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02682693CT.gov Denosumab as an add-on Neoadjuvant Treatment (GeparX) | — | Completed | — | — | — |
NCT02125344CT.gov A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Invasive Ductal Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pertuzumab (this asset) | GBG Forschungs GmbH | P3 | BB · 68 |
| Carboplatin | GBG Forschungs GmbH | P3 | BBB |
| Letrozole | University of Washington | P4 | BBB |
| Cyclophosphamide | UMC Utrecht | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | RenJi Hospital | P3 | BB |
| Trastuzumab | GBG Forschungs GmbH | P3 | BB |
| Epirubicin | GBG Forschungs GmbH | P3 | BB |
| Fulvestrant | G1 Therapeutics, Inc. | P3 | BB |
| Ferric Cation | GBG Forschungs GmbH | P3 | BB |
+27 more in the Invasive Ductal Breast Carcinoma cohort
Other indications for Pertuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BBB · 75 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 72 |
| Breast Cancer | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Pertuzumab in Invasive Ductal Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-neu-receptor-human-mouse-monoclonal-2c4-heavy-chain-disulfide-with-human-mouse-monoclonal-2c4-kappa-chain-dimer-invasive-ductal-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →